Targacept launches Phase 2 study
Targacept has launched a Phase 2 study of a drug it calls TC-5214 as a potential therapy for resistant hypertension.
Targacept Inc. today announced management changes that include the formation of an Office of the Chairman led by Mark Skaletsky, Chairman of Targacept's Board of Directors.